ArticleJournal of medicinal chemistry2026
Neuropilin-1-Targeted Cell-Penetrating Tandem Peptide-Drug Conjugate Exhibits Potent In Vivo Antiglioma and Antiangiogenic Activity.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most therapeutics for brain malignancies are limited by poor blood-brain barrier (BBB) transport and inadequate tumor penetration. Combining a BBB-penetrating peptide (SynB3) with a neuropilin-1 (NRP-1) receptor-targeting peptide (tuftsin) offers a promising strategy to enhance brain delivery, glioma targeting, and tumor penetration. This study demonstrated that SynB3, tuftsin, and their tandem construct bind in silico to the NRP-1 b1 pocket, corresponding to the C-end rule motif interaction site. Their cellular internalization likely involves macropinocytosis. The peptides penetrated 3D glioma spheroids, and the attached cargo did not significantly modulate their penetration. Dau-conjugates consistently inhibited proliferation in four glioblastoma cell lines and showed adequate in vitro stability in mouse plasma. In a subcutaneous murine model, Dau-SynB3 and the tandem conjugate reduced tumor volume and weight, prolonged tumor doubling time, and demonstrated improved tolerability compared with free Dau. Both conjugates exhibited antiproliferative effects, while the tandem construct additionally showed antiangiogenic activity ex vivo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.